Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort.

  • Hughes, Timothy P. (Primary Chief Investigator (PCI))
  • Hiwase, Devendra Keshaorao (Chief Investigator (CI))
  • Ross, David Morrall (Chief Investigator (CI))
  • Reynolds, John (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date1/06/20 → 31/05/25

Keywords

  • Myelomonocytic Leukaemia
  • Lenzilumab
  • Ascorbate